Constitutive activation of STAT transcription factors in acute myelogenous leukemia
about
sameAs
Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Safety evaluation of ruxolitinib for treating myelofibrosis.Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphomaInvestigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia.Signal transducer and activator of transcription 3 (STAT3) gene polymorphisms are associated with treatment outcomes in acute myeloid leukemia.Mutation of Cys105 inhibits dimerization of p12CDK2-AP1 and its growth suppressor effect.Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicStat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformationImpact of high glucose on metastasis of colon cancer cellsBigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells.The synthetic tryptanthrin analogue suppresses STAT3 signaling and induces caspase dependent apoptosis via ERK up regulation in human leukemia HL-60 cells.The Immunohistochemical Expression of STAT3, Bcl-xL, and MMP-2 Proteins in Colon Adenoma and Adenocarcinoma.JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.STAT proteins as novel targets for cancer drug discovery.Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma.Two Modes of the Axonal Interferon Response Limit Alphaherpesvirus NeuroinvasionIdentification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group reportZ3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.STAT3 as a target for inducing apoptosis in solid and hematological tumorsStat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiencyTargeting signal transducer and activator of transcription signaling pathway in leukemias.Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.STAT signaling in the pathogenesis and treatment of myeloid malignancies.Caspase-3 and caspase-6 cleave STAT1 in leukemic cellsTargeting acute myeloid leukemia stem cell signaling by natural products.Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis.Signal transducer and activator of transcription 6 down-regulates toll-like receptor-4 expression of a monocytic cell line.Constitutive tyrosine and serine phosphorylation of STAT4 in T-cells transformed with HTLV-I.Vanadate stimulates monocytic differentiation activity of IL-6 by enhancing actin filament polymerization in HL-60 cells.The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion.Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3.
P2860
Q28830045-F7CF2F9A-2A15-47B1-A4D7-4AD27E6D24EBQ33341856-09DCFA69-2783-4266-AF91-760537395A5BQ33415731-DB9F204D-7F4B-483A-8003-5C415244DA90Q33761711-49E0D1DE-EFFB-421A-9E35-D06F9FAD6EFCQ34085965-C04B8A75-B745-42B1-8E89-CB99EA75EC49Q34178810-5DCEA7E0-BDD1-4382-82F0-03C389EB6201Q34412512-44906985-130D-431C-8710-D2E23409772BQ34650656-221ECA1E-B298-4058-8FA7-4D2A42B9030FQ34796524-8F585746-E24E-4DC9-BD2E-9213C5B8B0DFQ34817365-65009F9F-4EC4-46F5-81C2-3B5315E46DD1Q35030931-08582AE1-7C79-4834-9953-E89FBDAA8FBBQ35060981-E8A28513-46B8-4B51-8A4A-C55FA53F5427Q35078012-1DF62031-4FA0-4343-9185-1786484C6D1AQ35289346-D0DECED7-90B4-40B3-AC9A-60B6F9A06491Q35406528-36B0E24E-E650-4E69-821E-B7858525DBDBQ35778326-33D833CC-2ECC-4831-A0D4-DF4C6F47516BQ35849213-F8DA39A5-56C7-44A3-9A2D-99092EE7878FQ35863370-28F67163-ECFB-4BE6-8615-1D3139F7DF6BQ35911116-1D953D99-07C3-4F89-9076-E04F6874FB21Q36067474-C0E38AC6-8652-4024-8C71-677D6074A201Q36548262-54EADBC2-6C20-4606-A10E-3ACD41F090BDQ36616527-B60C473D-FDF3-4FC5-9CF1-D341889F5CCEQ36619682-91B44869-DDE4-4F46-B6CD-F567ACAA3D12Q36963919-AB5829B3-5793-4CEC-A838-574A806BA6EFQ37029162-083AF39C-72DE-49CE-985B-4AD3FCCBDB70Q37304113-4C52029B-83C2-4F2D-A7F3-E77C67C3BAA8Q37347522-22DE371B-7D41-4970-88F7-4DA521EFE95CQ37457673-D33C1AF7-8CEE-4AC8-A7A6-11424EE7CDE9Q38140880-A77F74AF-7191-4EA9-BD57-7E19FA8BAA9BQ38997038-4A7ED248-6080-410C-988C-1997872C6C1AQ39109921-213D49BE-992F-4144-9414-5680BDD5A569Q40235023-C3B8BAAB-A653-4B69-9B6F-14B3077CA503Q40262816-E1D82518-0026-4968-8CFC-58FF9ABCD9B7Q40325733-5BE86A0F-CCE3-47A4-ABBC-17371F7D0FA9Q40344556-F136D10E-61EB-420E-BDCF-03FA9ECDEF6FQ40481809-4F29092E-65DE-4B44-9359-F249E9AA7722Q42716207-87416DEE-CD05-4845-ABE3-9C1912703FDBQ42720284-B3DB6295-005B-434D-84D1-5EED276BA100Q42964796-8E96EF07-E90E-44EA-989A-81A1FE4C8FFEQ43189037-C9E5D368-F3D7-4A7C-B0ED-909AAF3224B9
P2860
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@ast
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@en
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@nl
type
label
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@ast
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@en
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@nl
prefLabel
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@ast
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@en
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@nl
P2093
P2860
P1476
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
@en
P2093
P2860
P356
10.1034/J.1600-0609.2001.00385.X
10.1034/J.1600-0609.2001.T01-1-00385.X
P407
P577
2001-08-01T00:00:00Z